Your browser doesn't support javascript.
loading
Efficacy and safety of dapagliflozin in children with kidney disease: real-world data.
Choi, Naye; Kim, Ji Hyun; Park, Peong Gang; Lee, Hyeonju; Min, Jeesu; Park, Hye Won; Ahn, Yo Han; Kang, Hee Gyung.
Afiliación
  • Choi N; Department of Pediatrics, Korea University Anam Hospital, Seoul, Republic of Korea.
  • Kim JH; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Park PG; Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Lee H; Department of Pediatrics, Ajou University School of Medicine, Suwon, Republic of Korea.
  • Min J; Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Republic of Korea.
  • Park HW; Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea.
  • Ahn YH; Suwon Center for Environmental Disease Atopy, Ajou University Hospital, Suwon, Republic of Korea.
  • Kang HG; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.
Pediatr Nephrol ; 2024 Aug 06.
Article en En | MEDLINE | ID: mdl-39103536
ABSTRACT

BACKGROUND:

Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has shown results in slowing estimated glomerular filtration rate (eGFR) decline and reducing proteinuria in adult patients with chronic kidney disease. This retrospective study examines dapagliflozin's effects in 22 children with kidney disease and proteinuria.

METHODS:

Children with a median age of 15.6 years were treated with dapagliflozin for > 3 months between July 2022 and December 2023. All children had been treated with either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for at least 1 month before starting dapagliflozin.

RESULTS:

The most common kidney disease diagnoses in this study included Alport syndrome (n = 7) and medication-resistant nephrotic syndrome or focal segmental glomerulosclerosis (n = 7). After 6.1 months of treatment, dapagliflozin treatment did not result in significant changes in eGFR or proteinuria. However, at the latest follow-up, a statistically significant decrease in eGFR was noted (65.5 compared to the baseline 71.1 mL/min/1.73 m2, P = 0.003). Proteinuria remained stable between baseline and the last follow-up (final spot urine protein/creatinine ratio (uPCR) 0.7 vs. baseline uPCR 0.6 mg/mg, P = 0.489). In the subgroup analysis of children treated for > 8 months, the eGFR decline post-treatment changed from - 0.5 to - 0.2 ml/min/1.73 m2 per month (P = 0.634). Only two children discontinued dapagliflozin due to suspected adverse events.

CONCLUSIONS:

Dapagliflozin has not been associated with serious side effects. Further prospective clinical trials are needed to confirm the efficacy and safety of dapagliflozin in children with kidney disease.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pediatr Nephrol Asunto de la revista: NEFROLOGIA / PEDIATRIA Año: 2024 Tipo del documento: Article Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pediatr Nephrol Asunto de la revista: NEFROLOGIA / PEDIATRIA Año: 2024 Tipo del documento: Article Pais de publicación: Alemania